Connect your AI

Ultragenyx Pharmaceutical RARE Income Tax

Income Tax at other companies

Eli LillyLLY

$1.45B+109%

AmgenAMGN

$265M+9.1%

Ionis PharmaceuticalsIONS

$218K+87.9%

Arrowhead ResearchARWR

$7K-99.6%

CRISPR TherapeuticsCRSP

$839K-24.3%

ModernaMRNA

$9M+28.6%

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's income tax?: Ultragenyx Pharmaceutical (RARE) reported income tax of $1M in Q1 2026.
How has Ultragenyx Pharmaceutical's income tax changed year-over-year?: Ultragenyx Pharmaceutical's income tax decreased by 0.0% year-over-year, from $1M to $1M.
What is the long-term trend for Ultragenyx Pharmaceutical's income tax?: Over 3 years (2021 to 2025), Ultragenyx Pharmaceutical's income tax has grown at a 52.3% compound annual growth rate (CAGR), from $1.04M to $3.69M.
What does income tax mean?: Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.